ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,961 to 3,980 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
3M Skin and Nasal Antiseptic vs Bactroban Nasal: Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.21 of 842

24 of 855

-0.3 points

-1.9 to 1.3

1,697NCT01313182

Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial322 of 871

325 of 825

-2.4 points

-7.0 to 2.2

1,696NCT01499511

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events, as Defined, or Death.110 of 849

119 of 846

-1.1 points

-4.4 to 2.2

1,695NCT00013611

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: All-cause Mortality81 of 849

77 of 846

0.4 points

-2.3 to 3.2

1,695NCT00013611

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Serious Disease Progression Events or Death19 of 849

28 of 846

-1.1 points

-2.7 to 0.5

1,695NCT00013611

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events49 of 849

66 of 846

-2.0 points

-4.5 to 0.4

1,695NCT00013611

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: Grade 4 Clinical Events203 of 849

186 of 846

1.9 points

-2.1 to 5.9

1,695NCT00013611

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: serious adverse events203 of 849

186 of 846

1.9 points

-2.1 to 5.9

1,695NCT00013611

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial39 of 872

33 of 822

0.5 points

-1.5 to 2.4

1,694NCT01499511

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

With History of Treatment Prior to Sertraline vs Without History of Treatment Prior to Sertraline: Factors Considered to Affect the Efficacy of Sertraline: History of Treatment Prior to Administration of Sertraline Hydrochloride398 of 489

1,046 of 1,202

-5.6 points

-9.7 to -1.8

1,691NCT00605865

Drug Use Investigation of Jzoloft.

Cervarix Pooled Group vs Engerix-B Pooled Group: Number of Male Subjects Reporting Medically Significant Conditions (MSCs), in a Subset of Subjects47 of 643

76 of 1,047

0.1 points

-2.4 to 2.7

1,690NCT00534638

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Absorb BVS vs XIENCE: Landmark Analysis on TLF and Components60 of 1,108

38 of 580

-1.1 points

-3.7 to 1.2

1,688NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth <35 Weeks Gestation122 of 1,113

66 of 574

-0.5 points

-3.9 to 2.5

1,687NCT01004029

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

TBP-PI-HBr vs Imipenem-cilastatin: deaths from any cause2 of 843

2 of 844

0.0 points

-0.6 to 0.6

1,687NCT06059846

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

TBP-PI-HBr vs Imipenem-cilastatin: serious adverse events29 of 843

22 of 844

0.8 points

-0.8 to 2.5

1,687NCT06059846

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Promus Element Plus vs SYNERGY: serious adverse events262 of 838

265 of 846

-0.1 points

-4.5 to 4.4

1,684NCT01665053

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

INV_MMR Group vs COM_MMR Group: Number of Subjects Reporting Any Fever350 of 1,126

179 of 555

-1.2 points

-6.0 to 3.5

1,681NCT02184572

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

LR-TRUS vs UHR-TRUS: serious adverse events3 of 839

3 of 837

-0.0 points

-0.7 to 0.7

1,676NCT02079025

Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer

BCG-Denmark vs Control: deaths from any cause1 of 838

3 of 838

-0.2 points

-0.9 to 0.4

1,676NCT04542330

Using BCG to Protect Senior Citizens During the COVID-19 Pandemic

BCG-Denmark vs Control: serious adverse events78 of 838

63 of 838

1.8 points

-0.9 to 4.5

1,676NCT04542330

Using BCG to Protect Senior Citizens During the COVID-19 Pandemic

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=199"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=199

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01313182-4bd46373",
        "title": "3M Skin and Nasal Antiseptic vs Bactroban Nasal: Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.",
        "summary": "21 of 842 against 24 of 855; risk difference -0.3 points, 95% interval -1.9 to 1.3; NCT01313182, Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin",
        "record": "/library/comparisons/NCT01313182-4bd46373",
        "nct_id": "NCT01313182",
        "kind": "outcome",
        "participants": 1697,
        "risk_difference": {
          "value": -0.0031295578613993423,
          "lower": -0.019000328432907176,
          "upper": 0.012666297651379412
        },
        "group_1": "21 of 842",
        "group_2": "24 of 855",
        "difference": "-0.3 points",
        "interval": "-1.9 to 1.3",
        "trial_title": "Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin"
      },
      {
        "id": "NCT01499511-32241691",
        "title": "ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial",
        "summary": "322 of 871 against 325 of 825; risk difference -2.4 points, 95% interval -7.0 to 2.2; NCT01499511, Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study",
        "record": "/library/comparisons/NCT01499511-32241691",
        "nct_id": "NCT01499511",
        "kind": "outcome",
        "participants": 1696,
        "risk_difference": {
          "value": -0.024249382458337687,
          "lower": -0.07036854018152244,
          "upper": 0.021954368500851543
        },
        "group_1": "322 of 871",
        "group_2": "325 of 825",
        "difference": "-2.4 points",
        "interval": "-7.0 to 2.2",
        "trial_title": "Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=200",
  "request_id": "smYweJABPaJLAJb2"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?